Corxel announced plans to go public in the US through a SPAC, continuing the return of blank-check-backed financings for biopharma. For early-stage and clinical-stage developers, SPAC routes can accelerate capital access compared with traditional IPO timelines, though closing conditions and investor appetite remain key variables. The company’s move underscores how developers are structuring equity events to preserve runway for pipeline execution amid a more selective licensing and M&A market.